Aurobindo Pharma ups the ante in oncology space - (Business Standard via NewsPoints Desk)

  • Aurobindo Pharma unveiled plans to develop more than 58 treatments for cancer, as reported Business Standard.

  • The drugmaker plans to initiate regulatory filings for some assets later this year, with manufacturing starting in 2018 and 2019.

  • "The portfolio comprises several products with potential first to file opportunities and 180-day market exclusivities," Aurobindo stated.

  • Meanwhile, in biosimilars, the company aims to commercialise and market assets acquired in its purchase of TL Biopharmaceutical, noting that the treatments could have a market size exceeding $25 billion.

  • The drugmaker is expecting to start clinical trials of a biosimilar of an anti-angiogenesis drug targeting multiple cancers obtained in the TL acquisition next year.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles